DCM
MDGL icon

Diag Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Diag Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$326K Buy
+2,890
New +$447K 0.37% 36

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Diag Capital Management's MDGL Position: Q4 2018 in Review

Diag Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q4 2018: 2,890 shares worth $326K. The stake represents 0.37% of the portfolio and ranks #36 among its holdings.

136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Diag Capital Management held 2,890 shares of Madrigal Pharmaceuticals worth $326K as of Q4 2018.
  • Madrigal Pharmaceuticals was a new Diag Capital Management position in Q4 2018.
  • Madrigal Pharmaceuticals made up 0.37% of Diag Capital Management's portfolio in Q4 2018, its #36 holding.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.